Advertisement

Microbiome Therapies Show Potential in Hepatic Encephalopathy

Published on: 

Patricia Bloom, MD, examines microbiome therapies for hepatic encephalopathy, FMT findings, and challenges in HE drug development.

Differences in gut microbiome composition and metabolic activity may help explain why some patients with hepatic encephalopathy (HE) continue to experience recurrent episodes despite lactulose and rifaximin. Emerging research suggests these differences could eventually help identify patients most likely to benefit from specific microbiome-directed therapies.¹,²

Patricia Bloom, MD, assistant professor and transplant hepatologist in the Division of Gastroenterology and Hepatology at Mayo Clinic in Rochester, Minnesota, discussed the potential for microbiome-targeted treatments, early findings with fecal microbiota transplantation (FMT), and challenges in HE trial design in an interview with HCPLive.

Bloom presented “Beyond Lactulose and Rifaximin: Emerging Pharmacological Approaches to Hepatic Encephalopathy and Quality of Life” during a joint session of the American Association for the Study of Liver Diseases (AASLD) and the Indian National Association for Study of the Liver at AASLD The Liver Meeting 2026, held November 5-9 in Denver, Colorado.¹

Why the Gut Microbiome Remains a Target in HE

Lactulose and rifaximin, the mainstays of HE management, both act within the gastrointestinal tract. Lactulose reduces intestinal ammonia absorption and influences microbial activity, while rifaximin alters gut microbial function. Their established roles provide a rationale for investigating additional interventions targeting the gut-liver-brain axis.

“I do think that microbiome targeted therapies are the most promising emerging therapeutic area in hepatic encephalopathy,” Bloom said.

However, Bloom emphasized the need to better understand the microbiome of patients who continue to experience HE despite standard therapy. She suspects these patients may have different underlying microbial and metabolic abnormalities, suggesting a single intervention may not benefit everyone.

Rather than developing therapies for HE as a uniform condition, Bloom described a potential approach in which treatments are matched to specific microbiome profiles.

Could Microbiome Biomarkers Personalize HE Treatment?

One potential target is butyrate, a short-chain fatty acid produced through bacterial fermentation of dietary fiber. Butyrate supports intestinal barrier integrity and may help regulate intestinal permeability and inflammation.

Bloom noted patients with HE tend to have reduced fecal butyrate levels, although the clinical significance of this finding may vary between individuals. She suggested some patients might benefit from interventions intended to increase intestinal butyrate production, while others may have different metabolic disturbances requiring alternative approaches.

Recent research provides additional support for investigating these differences. A multi-omic analysis of the phase 2 THEMATIC trial evaluated microbial composition, metabolites, and inflammatory markers among patients with and without HE recurrence.³

Among the 60 participants, 10 experienced HE recurrence during 6 months of follow-up. Investigators observed lower abundance of several short-chain fatty acid-producing bacterial groups among patients with recurrence, along with differences in circulating metabolites and neurotransmitter-related pathways.³

These associations suggest microbial and metabolic signatures may help characterize recurrence risk, although they do not establish biomarkers capable of guiding treatment selection in routine practice.

Bloom envisioned a future diagnostic approach using baseline microbial composition or metabolite measurements to identify patients most likely to benefit from particular therapies. Such a strategy would require prospective validation before clinical implementation.

THEMATIC Trial Provides Early Evidence for FMT in HE

Among microbiome-directed interventions, Bloom identified FMT as having the strongest early clinical evidence.

The phase 2 THEMATIC trial, led by Jasmohan S. Bajaj, MD, enrolled 60 patients with cirrhosis and prior overt HE who were receiving lactulose and rifaximin. Participants were randomized across 4 groups receiving different combinations of oral capsule and enema FMT or placebo and followed for 6 months.²

The primary endpoint assessed FMT-related adverse events and serious adverse events. No FMT-related adverse events were reported, and overall serious adverse events and mortality were similar across groups.

HE recurrence was evaluated as a secondary outcome. Recurrence differed significantly across the 4 treatment groups (P = .035). In a post hoc comparison, recurrence occurred in 40% of patients receiving placebo alone versus 9% receiving any FMT (OR 0.15; 95% confidence interval [CI], 0.04-0.64).²

The findings suggest a potential role for FMT in reducing recurrence, although the small sample size and exploratory nature of the comparison limit conclusions about efficacy.

Investigators also observed differences in donor microbiota engraftment, with lower engraftment associated with HE recurrence. These findings raise additional questions about whether baseline microbial characteristics could influence treatment response.

Bloom emphasized the need for larger trials before the efficacy and longer-term safety of FMT can be established.

Two ongoing investigations may provide additional evidence. The phase 3 PROMISE trial in the United Kingdom is designed to enroll 300 patients with cirrhosis and evaluate encapsulated FMT, with a primary endpoint of time to infection or decompensation requiring emergency care or hospitalization.⁴

In Denmark, the randomized ChiFT trial is designed to enroll 220 patients with acute decompensation of cirrhosis, with time to new decompensation or death as its primary endpoint.⁵

Neither trial focuses specifically on HE recurrence as its primary endpoint, but both may provide insight into the broader clinical effects and safety of microbiome-directed treatment in advanced liver disease.

Defined Bacterial Consortia and Synbiotics Offer Other Approaches

Although FMT introduces a broad community of microorganisms, the variability of donor-derived preparations creates challenges for product standardization and safety assessment.

Bloom suggested defined bacterial consortia may offer advantages because their microbial composition can be controlled and reproduced more consistently than conventional donor-derived FMT.

These products could allow investigators to evaluate specific bacterial communities and their metabolic effects while reducing some of the variability associated with donor material.

Another potential approach involves synbiotics, which combine beneficial microorganisms with substrates intended to support their growth or activity.

Bloom raised the possibility of pairing selected bacterial strains with prebiotic fibers to promote desired metabolic functions, including short-chain fatty acid production.

However, these approaches remain investigational in HE. Their optimal composition, dosing, patient selection, and clinical effects require further study before they can be considered established treatment options.

RED-C Results Highlight Challenges in HE Trial Design

Beyond identifying new therapeutic targets, Bloom emphasized the importance of selecting appropriate patients and clinical endpoints for HE trials.

In January 2026, Bausch Health announced that both phase 3 RED-C trials evaluating amorphous rifaximin solid soluble dispersion (SSD) for primary prevention of HE in adults with cirrhosis failed to meet their primary endpoints. The company reported the investigational formulation was safe and well tolerated.⁶

Unlike studies focused on recurrent HE, the RED-C program evaluated prevention of a first episode of overt HE.

Bloom explained the rationale for the formulation involved the dependence of conventional rifaximin on intestinal bile acids for dissolution and availability. Because patients with cirrhosis may have altered intestinal bile acid composition, a formulation intended to improve drug availability offered a plausible therapeutic approach.

However, Bloom cautioned that the complete trial findings were not available to her and that her interpretation of the unsuccessful results was speculative.

She suggested patient selection may have contributed to the difficulty of demonstrating benefit, particularly if participants were not at sufficiently high risk of developing overt HE during the study period.

“You do need to select patients for your trial who are going to have the outcome,” Bloom said. “So you need to be really careful about the criteria you’re using to select those people who are truly highest likelihood of developing overt encephalopathy.”

Ascites illustrates this challenge. Bloom noted patients with small amounts of ascites responsive to low-dose diuretics may have a different risk of developing overt HE than patients with more advanced decompensation.

Enrolling patients at higher risk could increase the likelihood of observing sufficient events to assess a preventive treatment. However, these patients may also experience competing complications, including spontaneous bacterial peritonitis, variceal bleeding, and other events affecting trial participation and outcome assessment.

Bloom described these competing risks as a persistent challenge in HE drug development.

The RED-C results do not establish patient selection as the reason the trials missed their endpoints. However, Bloom's discussion highlights the importance of identifying populations with sufficient event risk while accounting for the complications of advanced liver disease.

For future HE therapies, demonstrating biological activity will be only one component of development. Investigators will also need to establish whether an intervention produces clinically meaningful reductions in HE episodes and improvements in patient outcomes.

Editor's Note: Bloom reports relevant disclosures with Nexilico and Vedanta Biosciences.

References
  1. Bloom P. Beyond Lactulose and Rifaximin: Emerging Pharmacological Approaches to Hepatic Encephalopathy and Quality of Life. Presented at: The Liver Meeting 2026; November 5-9, 2026; Denver, CO.
  2. Bajaj JS, Fagan A, Gavis EA, et al. Microbiota transplant for hepatic encephalopathy in cirrhosis: the THEMATIC trial. J Hepatol. 2025;83(1):81-91. doi:10.1016/j.jhep.2024.12.047
  3. Bajaj JS, Fagan A, Sterling RK, et al. The multi-omic basis for hepatic encephalopathy recurrence: analysis of the THEMATIC trial. JHEP Rep. 2026;8(1):101634. doi:10.1016/j.jhepr.2025.101634
  4. PROMISE trial investigators. PROMISE: a prospective randomised double-blind parallel group placebo-controlled multicentre trial of faecal microbiota transplantation to improve outcomes in patients with cirrhosis over 24 months-study protocol for a clinical trial. Trials. 2026. Study protocol.
  5. Støy S, et al. Cirrhosis and Faecal microbiota Transplantation (ChiFT) protocol: a Danish multicentre, randomised, placebo-controlled trial in patients with decompensated liver cirrhosis. BMJ Open. 2025. doi:10.1136/bmjopen-2024-091078
  6. Bausch Health provides update on RED-C phase 3 clinical trials. News release. Bausch Health. Published January 23, 2026. Accessed November 16, 2026. https://ir.bauschhealth.com/news-releases/2026/01-23-2026-124516159

Advertisement
Advertisement